FDA OKs Hyalex Ortho’s Slalom MTP Hemiarthroplasty Implant

Hyalex Orthopaedics has gained U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hyalex Slalom MTP hemiarthroplasty implant.

The next-generation implant was designed around the company’s proprietary Hydrosurf materials platform. It’s indicated to treat degenerative conditions affecting the first metatarsophalangeal (MTP) joint, including hallux rigidus.

The Slalom implant was engineered to restore joint function while preserving bone and soft tissue. Its breakthrough Hydrosurf material is a surface technology designed to closely replicate native cartilage’s biomechanical properties. With an advanced implant geometry, Hyalex said the system is designed to reduce pain, maintain range of motion, and offer a reliable alternative to traditional fusion procedures.

The FDA nod enables the company’s first commercial product launch in the U.S. and marks its entry into the foot and ankle reconstruction market.

Hyalex is beginning a limited U.S. market release bolstered by targeted surgeon training programs and strategic channel buildout. After limited release, the company expects a full commercial rollout later this year.

The company believes the Slalom MTP implant could drive adoption in a sizable and underpenetrated segment of the orthopedic extremities market.

First MTP joint arthritis often leads to pain, stiffness, and reduced mobility. Current surgical options like arthrodesis (fusion) eliminate joint motion—the Slalom MTP is a motion-preserving alternative aligned with surgeon and patient preferences.

“The FDA clearance of the HYALEX Slalom MTP Implant is a pivotal milestone that validates our technology and accelerates our transition into a commercial-stage company,” said Carl Vause, CEO of Hyalex Orthopaedics. “We believe this system addresses a significant unmet clinical need while opening a meaningful market opportunity for tissue and motion-preserving solutions in first MTP joint disease. This clearance establishes the foundation for future growth and portfolio expansion.”

In May 2025, the company earned FDA approval for a supplemental Investigational Device Exemption (IDE) study for its Freestyle knee implant.